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Background: The fecal immunochemical test (FIT) is commonly used for colorectal cancer 
(CRC) screening. Despite demographic variations in stool hemoglobin concentrations, little data 
exist regarding optimal positivity thresholds by age and sex.
Objective: Identify programmatic (multi-test) FIT performance characteristics and optimal FIT 
quantitative hemoglobin positivity thresholds in a large, population-based screening program.
Design: Retrospective cohort study
Setting: Kaiser Permanente Northern and Southern California
Participants: Adults 50–75 years of age, screening eligible, with baseline quantitative FIT 
results (2013–2014), and 2 years follow-up. Nearly two-thirds (411,641) had a previous FIT 
within 2 years.
Measurements: FIT programmatic sensitivity for CRC and number of positive tests per cancer 
detected, overall and by age and sex.
Results: Among 640,859 persons completing a baseline FIT and followed for 2 years, 481,817 
(75%) had ≥1 additional FIT and 1,245 (0.19%) were diagnosed with CRC. Cancer detection 
(programmatic sensitivity) increased at lower positivity thresholds, from 925/1,245 (74.3%) at 30 
μg/g, to 950 (76.3%) at 20 μg/g, and 987 (79.3%) at 10 μg/g; the number of positive tests per 
cancer detected increased from 43 at 30 μg/g, to 52 at 20 μg/g, and 85 at 10 μg/g. Reducing the 
positivity threshold from 20 to 15 μg/g would detect 3% more cancers and require 23% more 
colonoscopies. At the conventional 20 μg/g FIT threshold, programmatic sensitivity decreased 
with increasing age (79.0%, 73.4%, and 68.9% for ages 50–59, 60–69 and 70–75 years, 
respectively, p=0.009) and was higher in men than women (77.0% vs. 70.6%, p=0.011).
Limitations: Information on advanced adenoma were lacking.
Conclusion: Increased cancer detection at lower positivity thresholds is counter-balanced by 
substantial increases in positive tests. Tailored thresholds may provide more comparable screening 
benefits for different demographic groups, dependent upon local resources.
Keywords
colorectal cancer; screening; fecal occult blood tests; sensitivity and specificity; number needed to 
scope
Introduction:
Colorectal cancer (CRC) is the second-leading cause of cancer mortality in the United States 
(US)(1). Screening with guaiac-based fecal occult blood tests reduced CRC mortality in 
randomized trials by 15 to 33% (2, 3). The fecal immunochemical test (FIT) has several 
advantages over guaiac-based tests, including greater specificity for human hemoglobin, the 
need for only a single fecal sample, and no requirement for dietary or medication restrictions 
(1, 4).
Quantitative FITs directly measure human hemoglobin concentrations in the stool. The 
quantitative threshold for a positive FIT result (positivity threshold) can be tailored to 
different settings and patient groups to optimize cancer detection (sensitivity), while limiting 
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the number of colonoscopies triggered by positive FIT results. Population-based screening 
programs worldwide use a broad range of FIT positivity thresholds, ranging from 10 to 47 
μg hemoglobin/g (5), although 20 μg/g is the convention in the US (6). Few comparisons 
between positivity thresholds exist from screening programs in large diverse populations (7, 
8). Furthermore, there are differences in fecal hemoglobin concentrations between 
population groups, with reports of higher concentrations in men than women and increasing 
concentrations with age (9–11). Likewise, CRC incidence is higher in men than women, and 
increases with age (12). In contrast, women have a higher incidence of proximal cancers 
(right sided) that may be more difficult to detect by screening (13, 14). Consequently, 
utilizing the same FIT positivity threshold across subgroups may be suboptimal (15). 
Previous studies examining positivity thresholds have been limited by an insufficient number 
of cancer diagnoses needed to define the sensitivity of FIT, particularly in demographic 
subgroups (4, 7, 14, 16–18), were conducted with population samples that did not resemble 
the general US population (19), used outdated or qualitative tests (4), or lacked 
comprehensive follow-up of negative FIT results needed to identify missed CRCs (i.e., false 
negatives)(20, 21).
We examined FIT screening performance measures in two large, community-based, 
screening programs using mailed FIT outreach with linkage to comprehensive cancer 
registries. We assessed the balance of cancer detection and screening burden at varying FIT 
positivity thresholds. Our goal was to quantify the programmatic sensitivity of FIT (over 
multiple rounds of testing) and the potential impact of various positivity thresholds on a 
screening program, in a cohort representative of a community-based, diverse population.
Methods
Study Setting:
This retrospective cohort study included members of Kaiser Permanente Northern California 
(KPNC) and Southern California (KPSC) who completed FIT screening between January 1, 
2013 and December 31, 2014. KPNC and KPSC are integrated healthcare systems with 
approximately 8 million members receiving care across 40 medical centers. These systems 
provide comprehensive care, an integrated electronic health record, and cancer registries 
reporting to the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End 
Results) program. Their diverse membership closely approximates the adult census 
population in California, except at extremes of income (22–24). The study was approved by 
the institutional review boards of KPNC and KPSC, and was conducted within the National 
Cancer Institute-funded Population-based Research to Optimize the Screening Process 
(PROSPR II) consortium, which conducts multisite, coordinated, transdisciplinary research 
to evaluate and improve cancer screening processes.
Fecal immunochemical tests:
KPNC and KPSC have organized FIT-based CRC screening outreach programs that began 
between 2006 and 2008 (8, 25). Members 50–75 years of age without a colonoscopy within 
10 years or sigmoidoscopy within 5 years were mailed a FIT kit annually. The kit included a 
one-sample FIT (OC FIT-CHEK; Polymedco), a standardized letter, directions for 
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completing the test, and a preprinted laboratory requisition form. Patients mailed their 
completed FIT to a regional laboratory, where it was analyzed using an OC-Sensor Diana 
automated system (Polymedco) with the threshold for a positive test of >20 μg/g 
(corresponding to 100 nanograms of hemoglobin/ml of test buffer) (26). Patients with a 
result at the threshold were classified as negative. Patients with positive results were referred 
for colonoscopy. Patients and providers were informed if the result was “positive” or 
“negative”, but were not provided with the actual quantitative values. Tests with a value 
>200 μg/g were read as “over assay” and reported as positive.
Overall cohort eligibility criteria and follow-up:
Individuals were eligible if they had a quantitative FIT result available between January 1, 
2013 and December 31, 2014, irrespective of whether it was their first-ever FIT; were 50–75 
years of age; were at average risk for CRC (no personal history of CRC, total colectomy, or 
inflammatory bowel disease); and had been members of the health system for ≥2 years 
before the test result date (to capture prior endoscopy examinations or FIT).Patients were 
followed for 2 years after the test result date or until their CRC diagnosis date if it was 
within 2 years.
Data sources:
Quantitative FIT values were obtained directly from the automated OC-Sensor Diana 
machine. Patient characteristics (date of birth, sex, body mass index (BMI), race and 
Hispanic ethnicity) were obtained from the electronic health record. The number of primary 
care visits and Charlson comorbidity scores were computed with a standardized algorithm 
using International Classification of Diseases, Ninth Revision codes from care episodes in 
the calendar year before the baseline FIT (27). Colorectal adenocarcinoma diagnoses were 
obtained from the KPNC and KPSC cancer registries, which capture greater than 99% of 
cancers diagnosed among members, compared with manual review, and include the cancer 
site, morphology, and stage. Cancers were diagnosed in three main ways: by colonoscopy 
done for follow-up of positive FIT; by colonoscopy or radiologic imaging exams done after 
negative FIT because of symptoms or laboratory abnormalities (e.g. anemia); and by 
colonoscopy after negative FIT because subsequent to the FIT, the patient elected to 
continue future screening with an elective colonoscopy. We only considered 
adenocarcinomas, which represent approximately 90–95% of all CRCs, because these 
tumors are believed to follow the adenoma-carcinoma sequence and are potentially 
preventable through screening (28, 29). Cancer location was defined as the right colon 
(proximal to the splenic flexure), left colon, or rectum. Advanced-stage cancers were defined 
as stage III (regional lymph node involvement) or stage IV (distant metastasis) according to 
the American Joint Committee on Cancer staging system or as code 3 (disease in the 
regional lymph nodes), code 4 (regional disease with direct extension and spread to regional 
lymph nodes), or code 7 (distant metastasis) according to the 2013 SEER Program Coding 
and Staging Manual 2013 (30).
Data Analysis:
The distribution of baseline quantitative FIT values among those with and without CRC 
during follow-up, by age and sex, were summarized using percentiles. The primary analysis 
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was the programmatic sensitivity, specificity, and corresponding confidence intervals at FIT 
positivity thresholds of 10, 15, 20, 25 and 30 μg/g. Programmatic sensitivity was the 
proportion of patients with a CRC diagnosis within 2 years of FIT screening who had a 
quantitative FIT result above a given positivity threshold at baseline or during follow-up 
testing; programmatic specificity was the proportion of patients without a CRC diagnosis 
with all quantitative FIT results at or below a given threshold. The number of cancers 
diagnosed and the number individuals with a positive test were calculated at each threshold. 
The number of participants with a positive test per cancer detected was calculated at each 
threshold. The same test characteristics were examined separately by age (50–59, 60–69 and 
70–75 years) and sex (male and female), with comparisons between subgroups using the χ2 
and ANOVA tests. Analyses were repeated using only the baseline FIT result and 1 year of 
follow-up in the cancer registry to evaluate the impact of a single test using the 
recommended 1-year screening interval in the United States, and to limit the effect of 
repeated screening on results (4). Analyses used SAS Version 9.4 (SAS Institute) and Stata 
Version 14 (StataCorp).
Role of Funding Sources:
The study was funded by the National Cancer Institute and the Swiss Cancer Research 
Foundation, neither of which had a role in the conception, design, analysis, or conduct of the 
study.
Results:
Overall cohort Characteristics:
Of 1,550,542 members who received a FIT, 1,212,461 (78%) completed ≥1 FIT in 2013–
2014 (Figure 1). A total of 640,859 patients (53%), including 401,975 at KPNC and 238,884 
at KPSC, had ≥1 quantitative FIT result and met the inclusion criteria; 411,241 (64%) 
completed a previous FIT within 2 years of the baseline FIT (Table 1). During 2 years of 
follow-up, 159,042 (25%) did not complete additional FIT screening after the baseline, 
250,519 (39%) completed 1 additional FIT, and 231,298 (36%) completed ≥2 additional 
FITs (Figure 1). A total of 48,561 (7.6%) patients had a positive result at the conventional 
positivity threshold of 20 μg/g, of whom 36,906 (76%) had a colonoscopy within 2 years of 
the baseline FIT (median 33 days after the result). The distributions of positive tests, 
colonoscopy follow-up, and cancer diagnoses were similar between those with quantitative 
results and the overall population of KPNC and KPSC members tested during the study 
period (data not shown).
Of 1,245 cancers diagnosed at or within 2 years of the baseline FIT, 505 (41%) were in the 
right colon, 358 (29%) in the left colon, 362 (29%) in the rectum, and 20 (1.6%) of 
undefined primary location (Table 1). The proportion of right-sided cancers increased with 
age (29% between 50–59 years, 44% between 60–69 years, and 53% between 70–75 years, 
p<0.001), and was higher in women than men (46% vs. 36%, p=0.004) (supplemental Tables 
1 and 2). Among those who did not develop cancer during follow-up, baseline stool 
hemoglobin values at the 95% percentile increased with age (13.4 μg/g for age 50–59, 16.2 
μg/g for age 60–69, and 21.0 μg/g for age 70–75, p<0.001), and were higher in men than 
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women (17.8 μg/g vs. 13.4 μg/g, p<0.001)(Supplemental table 3). For those who developed 
cancer, median stool hemoglobin values from the baseline FIT were higher for left-sided 
than right-sided cancers or rectal cancers (60.0 μg/g, 12.4 μg/g, and 24.4 μg/g respectively, 
p<0.001 for each 2-way comparison)(Supplemental table 3).
FIT performance at varying positivity thresholds in the overall cohort:
The proportion of cancers detected by FIT (programmatic sensitivity) decreased with higher 
positivity thresholds, from 987 of 1,245 cancers at 10 μg/g (79.3%), to 925 at 20 μg/g 
(74.3%), and 822 at 30 μg/g (66.0%) (Table 3). The number of participants with a positive 
baseline or subsequent FIT test also decreased, from 84,293 at 10 μg/g (13.2% with positive 
test, programmatic specificity 87.0%), to 48,561 at 20 μg/g (7.6% with positive test, 
specificity 92.6%), and 35,017 at 30 μg/g (5.5% with positive test, specificity 96.8%).
The number of positive tests per cancer detected increased substantially at thresholds below 
20 μg/g. Positive tests per cancer detected increased 11% from 25 to 20 μg/g (47 to 52), 22% 
from 20 to 15 μg/g (52 to 63), and 35% from 15 to 10 μg/g (63 to 85). Reducing the 
positivity threshold from 20 to 15 μg/g would have detected 25 additional cancers (3% 
increase) from 11,308 additional colonoscopies (23% increase), equating to 452 
colonoscopies per additional cancer detected.
FIT performance at varying positivity thresholds stratified by age:
Programmatic sensitivity and specificity decreased significantly with increasing age at 
thresholds between 10 and 30 μg/g. At 20 μg/g, the programmatic sensitivity decreased from 
79.0% (95%CI 74.8–82.7) among those 50–59 years, to 73.4% among those 60–69 years 
(95%CI 69.4–77.1), and 68.9% among those 70–75 years (95%CI 63.2–74.3, p=0.009)
(Table 4). Programmatic specificity declined with age, from 93.5% (95%CI 93.4–93.6) 
among those 50–59 years, to 90.6% (95%CI 90.4–90.8) among those 70–75 years 
(p<0.001), as the number of positive tests per cancer detected decreased from 63 (57–70) to 
40 (35–47).
FIT performance at varying positivity thresholds stratified by sex:
At all thresholds between 10 and 30 μg/g, FIT had lower programmatic sensitivity and 
higher programmatic specificity among women than men (Table 4). At 20 μg/g, the 
programmatic sensitivities were 77.0% (95%CI 73.7–80.0) and 70.6% (95%CI 66.6–74.5) 
for men and women respectively (p=0.011), and the programmatic specificities were 91.6% 
(95%CI 91.5–91.7) and 93.4% (95%CI 93.3–93.5) (p<0.001). Decreasing the threshold from 
20 to 10 μg/g led to substantial increases in the number of positive tests per cancer detected 
for both sexes, increasing 62% from 47 (95%CI 43–51) to 76 (95%CI 70–83) in men, and 
63% in women from 60 (95%CI 55–67) to 98 (95%CI 89–108). Decreasing the threshold for 
women from 20 to 10 μg/g yielded a programmatic sensitivity similar to that of men at the 
20 μg/g threshold, but with a lower programmatic specificity (88.2% vs. 91.6%) and more 
than double the number of positive results per cancer detected (98 vs. 47).
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Additional analyses with 1-year follow-up:
Similar patterns were seen for the trade-off of sensitivity and specificity, both overall and 
among subgroups, using only 1-year of follow-up from the baseline FIT result 
(Supplementary Materials). FIT sensitivity of the baseline test only with 1-year of follow-up 
was slightly higher (77.7% at 20 μg/g (95%CI 72.6–81.0)) compared to the programmatic 
sensitivity with 2 years of follow-up (74.3% (95%CI 71.8–76.7); FIT specificity was also 
higher (95.9% (95%CI 95.9–96.0) vs. a programmatic specificity of 92.6% (95%CI 92.5–
92.6) (Supplemental Table 6).
Discussion:
In this large, diverse, community-based sample of adults participating in FIT screening, 
programmatic sensitivity for CRC increased modestly with decreasing positivity thresholds, 
from 74.3% at 20 μg/g, to 76.3% at 15 μg/g, and 79.3% at 10 μg/g. The number of positive 
tests per cancer detected over 2 years increased with decreasing positivity thresholds, 
especially below 20 μg/g. FIT performance varied by age and sex, with lower programmatic 
sensitivity and specificity with increasing age, and higher programmatic sensitivity and 
lower specificity in men than women.
The 5% point increase in CRC programmatic sensitivity observed when decreasing the 
positivity threshold from 20 to 10 μg/g is smaller than differences reported in some prior 
studies (31), although prior reports have been inconsistent and had small numbers of 
cancers, resulting in low precision (wide confidence intervals) (32–34). A systematic review 
of several FIT brands found that a threshold of <20 μg/g yielded an overall sensitivity of 
86% (95%CI 75–92) vs. 63% (95%CI 43–79) for thresholds between 20–50 μg/g (4). 
Previous studies with colonoscopy follow-up of all screening participants have compared 
FIT sensitivity (using OC-Sensor Diana) for advanced adenomas at varying thresholds (32–
35). They have shown 5–10% increases in advanced adenoma sensitivity when decreasing 
the positivity threshold from 20 to 10 μg/g. This increase is larger than we observed for 
cancers, and is clinically relevant given that approximately 25% of advanced adenomas will 
progress to CRC over 10 years (36).
A few prior studies with colonoscopy follow-up suggested that FIT sensitivity for CRC and 
advanced adenomas is higher and specificity lower in men than women (10, 34, 37), though 
reports are conflicting and did not allow precise estimates by quantitative FIT thresholds 
(19). Proposed explanations for this disparity include a higher proportion of harder-to-detect, 
right-sided cancers (34), lower serum hemoglobin concentrations (10), and longer colonic 
transit times in women than in men (38). Women in our cohort had a higher proportion of 
right-sided cancers than men, and women with cancer had lower mean stool hemoglobin 
concentrations than men with cancer (Supplemental table 3). Women also had smaller 
relative reductions in CRC mortality than men in previous randomized trials of guaiac tests 
(39). The apparent lower sensitivity of FIT in women is concerning given that 
sigmoidoscopy also appears less effective in women (40). There are few published reports of 
FIT performance trends by age, though FIT may perform better below age 50 than above 
(41), and worse above age 65 (42).
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Our findings suggest that screening programs wishing to increase cancer detection by 
lowering their positivity threshold below the conventional 20 μg/g will require substantial 
additional colonoscopy and financial resources. The large increases in the number of 
positive tests per cancer detected are likely because CRC is rare in screening populations 
and more overlap in lower fecal hemoglobin concentrations between those with and without 
CRC. Some additional colonoscopies generated by positive tests without a cancer (false 
positives in this study) would detect and remove advanced adenomas, likely reducing future 
cancer incidence (8, 31). However, repeat annual testing can mean larger accumulated 
numbers of false positive tests; our 2-year programmatic specificity results were 
substantially lower than one-time test specificity with 1-year follow-up (supplementary 
materials). The optimal positivity threshold (acceptable number of positive tests per cancer 
detected) will depend on the availability of local colonoscopy resources. Lower resourced 
settings may raise their positivity threshold, although in our study sensitivity at 30 μg/g 
declined from 74.3% to 66.0%. Notably, a screening program in the Netherlands increased 
their threshold from 15 to 47 μg/g following unexpectedly high colonoscopy demand (43).
The implications for screening programs of the observed differences in programmatic 
sensitivity and specificity by age and sex are less clear, and likely depend on the relative 
importance given to colonoscopy burden or maximizing cancer detection across subgroups. 
As might be expected, given the lower baseline fecal hemoglobin concentrations in women, 
we observed a larger increase in programmatic sensitivity when decreasing the positivity 
threshold from 20 to 10 μg/g in women than in men (7.1% vs. 3.5% increase), although 
women also had a larger increase in the number of positive tests per cancer (38 vs. 29 more 
tests), likely due to their lower cancer incidence rates. Lowering the positivity threshold for 
women may achieve comparable sensitivity to men and fewer interval cancers (34, 44), 
although others have proposed more aggressive screening in men due to their higher risk 
(12, 45, 46). We are not aware of previous work advocating lower positivity thresholds in 
older age groups. While FIT programmatic sensitivity and the number of positive tests per 
cancer detected were lowest in those aged 70–75 years, both the risk of cancer and the risk 
of complications from colonoscopy increase with age (1).
Strengths of our study include a diverse, multi-center community-based screening cohort, 
with quantitative FIT results available, including from repeated testing; analyses from 
multiple laboratories; high overall screening rates, decreasing the potential for selection bias 
(47); high-quality cancer registries; more cancers than previous studies (7, 16–18); and a US 
screening population (19, 32).
Our study also has several potential limitations. First, we did not have quantitative FIT 
values available on all members who underwent FIT screening during the study interval. 
However, analyses by season and medical center did not reveal any pattern in missing 
quantitative values, and our positive predictive values were similar to previous publications 
from the entire population, including those without quantitative values (8, 48). Second, we 
assumed all cancers with quantitative values ≤20 μg/g would be detected if designated 
positive; although follow-up colonoscopy rates and cancer registry ascertainment are high in 
the KPNC and KPSC screening programs (49), imperfect follow-up would likely attenuate 
the benefit of lowering the positivity threshold. Third, despite cancer registry follow-up, 
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estimates of programmatic sensitivity incorporate some differential verification bias: patients 
with a FIT result >20 μg/g were likely to receive immediate, invasive ascertainment sensitive 
for early-stage CRC (colonoscopy), rather than clinical follow-up with less sensitive 
ascertainment (cancer registry). Differential verification bias falsely increases sensitivity in 
studies of 1-time fecal-based cancer screening because of incomplete accrual of false 
negatives (50), and could make the current threshold of 20 μg/g appear more advantageous. 
However, our primary results focus on the performance of a screening program over 2 years 
rather than a single FIT. Fourth, we could not measure false negatives for advanced 
adenomas and thus our findings may reflect only part of the benefit of lower positivity 
thresholds. However, smaller studies have been able to estimate the effect of varying 
positivity thresholds on advanced adenoma detection using the same FIT brand (OC-Sensor 
Diana) (32–35). Fifth, because participants were followed for two calendar years and not 
precisely two rounds of screening, there may not have been sufficient time for colonoscopy 
follow-up of positive tests occurring towards the end of the 2-year follow-up. Finally, most 
participants had prior FIT screening, which, by removing some prevalent cancers, may have 
increased the number of positive tests per cancer detected as compared to screening naïve 
populations (8). However, as screening programs mature, it is important to measure test 
performance in heterogeneous populations of first-time and repeat screenees.
Conclusions
Among participants in a FIT-based screening program followed for 2 years from their 
baseline FIT, cancer detection and the number of positive tests per cancer detected varied 
significantly and substantially by age and sex, suggesting that modifications in positivity 
thresholds by subgroups could optimize screening program performance, although also with 
impacts on the number of false-positive tests. Modifying the positivity threshold for the 
overall study population from the current US conventional value of 20 to 15 μg/g would 
have resulted in 25 additional cancers detected (3% increase), and required the evaluation of 
11,308 additional positive tests (23% increase). Further research is needed to assess the cost-
effectiveness of such changes and practicality across settings with differing resources.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Number of fecal immunochemical tests (FIT) completed, FIT results, number of 
colonoscopies, and cancer diagnoses among patients with ≥1 FIT completed in 2013–2014 
and followed for 2 years from their baseline FIT. aInreach is the local distribution of FIT by 
primary care staff or otherwise. bInclusion criteria: 50–75 years of age; ≥2 years Kaiser 
Permanente membership prior to baseline FIT; no prior diagnosis of inflammatory bowel 
disease or CRC; no prior colectomy; and quantitative values available for all FITs during 2-
year study interval. Patients followed for 2 years after the baseline FIT. c2-year time interval 
started at time of the baseline FIT. Overall, 80% of patients received a colonoscopy within 
180 days of a positive FIT. d226,984 completed 2 additional FIT, 4,161 completed 3 
additional FIT, and 153 completed 4 additional FIT during the 2-year follow-up. FIT: fecal 
immunochemical test, CRC: colorectal cancer
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Table 1:
Patient characteristics and colorectal cancer outcomes within 2 years of a baseline fecal immunochemical test 
(FIT) among participants who completed ≥1 FIT (n=640,859)
Participant Characteristics
Female sex 337,588 (53%)
Age at time of FIT
 50 to 59 years 323,855 (51%)
 60 to 69 years 234,665 (37%)
 70 to 75 years 82,339 (13%)
Race/ethnicity
 Non-Hispanic white 352,913 (55%)
 Hispanic 114,724 (18%)
 Black 46,925 (7%)
 Asian/Pacific islander 103,958 (16%)
 Other or unknown 22,339 (3%)
Obese (BMI ≥30 kg/m2)a 215,312 (34%)
Primary care visits in year preceding test
 No primary care visit 124,285 (19%)
 1 to 3 primary care visits 367,406 (57%)
 4 or more primary care visits 149,168 (23%)
Charlson comorbidity score year prior to baseline FIT
 Score = 0 443,577 (69%)
 Score = 1 or 2 153,825 (24%)
 Score ≥ 3 43,457 (7%)
Previous FIT within 2 years of baseline FIT
 Yes 411,241 (64%)
 No 229,618 (36%)
Outcomes during follow-up
Colonoscopy within 2 years 97,651 (15%)
Baseline FIT > 20 μg/g 26,654 (4.2%)
Colorectal cancer diagnosed within 2 years of baseline FIT 1,245 (0.19%)
 Right-sided colon cancer 505 (41%)
 Left-sided colon cancer 358 (29%)
 Rectal cancer 362 (29%)
 Location unknown 20 (2%)
Colorectal cancer stage at diagnosis
 Early 1,064 (85%)
 Late 181 (15%)
a
Body mass index (BMI) was missing for 15,360 patients (2%). FIT: fecal immunochemical test
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